CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.

@article{Riser2009CCN3I,
  title={CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.},
  author={Bruce L. Riser and Feridoon Najmabadi and Bernard Perbal and Darryl R. Peterson and Jo Ann Rambow and Melisa L. Riser and Ernest J Sukowski and Herman Yeger and Sarah C. Riser},
  journal={The American journal of pathology},
  year={2009},
  volume={174 5},
  pages={1725-34}
}
Fibrosis is a major cause of end-stage renal disease, and although initiation factors have been elucidated, uncertainty concerning the downstream pathways has hampered the development of anti-fibrotic therapies. CCN2 (CTGF) functions downstream of transforming growth factor (TGF)-beta, driving increased extracellular matrix (ECM) accumulation and fibrosis. We examined the possibility that CCN3 (NOV), another CCN family member with reported biological activities that differ from CCN2, might act… CONTINUE READING